Durvalumab extends survival in SCLC but cost-effectiveness questioned
Durvalumab extends survival in small cell lung cancer while raising critical cost-effectiveness concerns. Researchers at the Sylvester Comprehensive Cancer Center (FL, USA) have unveiled findings from the ADRIATIC clinical trial, showing that durvalumab, an immune checkpoint inhibitor, significantly improves survival for patients with limited-stage small cell lung cancer (LS-SCLC). Led by Chinmay Jani and published … Read more